Is it unethical to conduct placebo-controlled trials of faecal microbiota transplantation for recurrent Clostridioides difficile infection?

Lancet Gastroenterol Hepatol. 2020 May;5(5):432-433. doi: 10.1016/S2468-1253(20)30043-1.

Authors

Colleen R Kelly¹, Stacy A Kahn²

Affiliations

¹ Division of Gastroenterology, Warren Alpert Medical School of Brown University, Providence, RI 02904, USA. Electronic address: colleen_r_kelly@brown.edu.
² Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA, USA.

PMID: 32277897
DOI: 10.1016/S2468-1253(20)30043-1

No abstract available

MeSH terms

Clostridioides difficile*
Controlled Clinical Trials as Topic / ethics*
Enterocolitis, Pseudomembranous / therapy*
Fecal Microbiota Transplantation* / adverse effects
Humans
Placebos / therapeutic use*
Recurrence
Therapeutic Equipoise

Substances

Placebos